1. Dianthus Therapeutics Inc. (NASDAQ:DNTH)
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125. The firm also reiterated its Strong Buy rating on the stock, which currently yields a revised upside potential of nearly 40%.
The company’s first quarter update showed a lot of progress with its drug pipeline, which included an orphan drug designation for its claseprubart program. The company is also prioritizing DNTH212, which is backed by the dual BDCA2 and BAFF/APRIL procedures.
Raymond James also made note of potential short-term catalysts for the company expected during 2026. These include Phase 1 data along with Phase 2 results for MMN expected during the final quarter. The company also aims to begin the Phase 3 study during mid-year, with a potential topline impact expected sometime in 2028.
On May 5, Dianthus Therapeutics Inc. (NASDAQ:DNTH) shared progress around the development of a rheumatology franchise with DNTH212 and moving claseprubart through critical trials in neuromuscular illnesses. The company is establishing itself as a pioneer in autoimmune disease treatments. Although the success will depend on providing solid clinical results across several categories, the $719 million financing offers considerable financial flexibility.
It is important to note that targeted treatments for severe and uncommon autoimmune diseases are becoming increasingly important in the biotech industry, and Dianthus’s pipeline may set it apart in an increasingly competitive marketplace.
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company that develops therapies for patients with severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody that blocks the C1s protein to stop immune overactivation effectively. The second one is DNTH212, which reduces interferon production and suppresses B-cell activity simultaneously.
While we acknowledge the potential of DNTH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DNTH and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
